Crispr Therapeutics vs Precigen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Crispr Therapeutics AG (CRSP)

Q3 202618 Jun – 24 Sep 2026

▲3▼1

CRISPR Q3: Casgevy pediatric approval, revenue jump, pipeline catalysts

Casgevy FDA approval for young children Casgevy won FDA approval for children as young as two, expanding the eligible U.S. patient pool by about 5,500 and opening a potential $12.1 billion market. This directly boosts future revenue prospects.
This is a major new approval that expands the market and is a key positive driver for the stock.
Q2 revenue surge and strong cash position Q2 revenue jumped 78% sequentially to $76 million, net loss narrowed, and $2.36 billion in cash funds years of operations. This shows improving financial health and reduces near-term funding risk.
Financial results are a key driver of investor sentiment and stock price.
Pipeline catalysts and competitive win Upcoming data for CTX310 (cholesterol) and CTX611 (clot therapy), plus off-the-shelf CAR-T, could drive value. Novartis's pelacarsen failure may boost CRSP's CTX321, and Ken Fisher opened a small stake.
Pipeline progress and competitive dynamics are important for future growth prospects.
Adoption challenges and valuation uncertainty Casgevy adoption is slow due to complex procedures, revenue is still tiny against continuing losses, CTX321's advantage is only animal-tested, and valuation is highly assumption-dependent. Analyst targets average $86.21, below one model's $221.98 fair value.
These risks could limit upside and are important counterweights to the positive drivers.

August 202612 Jul – 24 Sep 2026

▲3

Casgevy sales jump, FDA widens label, and a rival's failure lifts CRSP's pipeline hopes

Casgevy revenue accelerates and FDA widens the label Q2 Casgevy revenue hit $76 million, up 78% from the prior quarter and 151% from a year ago, and the FDA approved it for children as young as 2, adding roughly 5,500 eligible patients. Net loss narrowed to $91.2 million from $208.5 million, with $2.36 billion in cash. Real sales and a bigger market make the gene-editing story less speculative, supporting the stock.
This is the clearest new fundamental proof that CRSP's only approved product is selling and its market is expanding.
Novartis heart-drug failure may push CRSP's next-gen program forward Novartis's pelacarsen failed its Phase 3 heart trial despite lowering Lp(a), a rival approach. Citi says this makes CRSP more likely to prioritize its more potent next-generation CTX321 Lp(a) candidate, and kept a Buy rating and $88 target. Less competition and a clearer pipeline focus help the stock, though CTX321's advantage is only shown in animals so far.
A competitor's failure directly changes CRSP's pipeline priorities and analyst view, a new force on the stock.
Ken Fisher's fund discloses a new CRSP stake Billionaire Ken Fisher's Fisher Asset Management opened a new position of 77,960 CRISPR Therapeutics shares worth about $4.25 million as of June 30, per 13F filings. A well-known investor buying in can draw attention and fresh demand to a beaten-down stock, though the position is small relative to CRSP's size.
A new institutional buyer is a fresh, concrete signal of outside money coming into the stock.
Valuation debate: cheap on cash-flow models, fair on book value One model pegs fair value at $221.98, implying the stock is deeply undervalued, while analyst targets average $86.21 and price-to-book sits near the industry average. CRSP still loses money on tiny revenue, so whether it is cheap depends entirely on assumptions about future Casgevy and pipeline sales. That uncertainty cuts both ways.
It frames the central bull-bear tension behind the stock's price without repeating any single event.

Latest12 Jul – 24 Sep 2026

▲3

Casgevy sales jump, FDA widens label, and a rival's failure lifts CRSP's pipeline hopes

Casgevy revenue accelerates and FDA widens the label Q2 Casgevy revenue hit $76 million, up 78% from the prior quarter and 151% from a year ago, and the FDA approved it for children as young as 2, adding roughly 5,500 eligible patients. Net loss narrowed to $91.2 million from $208.5 million, with $2.36 billion in cash. Real sales and a bigger market make the gene-editing story less speculative, supporting the stock.
This is the clearest new fundamental proof that CRSP's only approved product is selling and its market is expanding.
Novartis heart-drug failure may push CRSP's next-gen program forward Novartis's pelacarsen failed its Phase 3 heart trial despite lowering Lp(a), a rival approach. Citi says this makes CRSP more likely to prioritize its more potent next-generation CTX321 Lp(a) candidate, and kept a Buy rating and $88 target. Less competition and a clearer pipeline focus help the stock, though CTX321's advantage is only shown in animals so far.
A competitor's failure directly changes CRSP's pipeline priorities and analyst view, a new force on the stock.
Ken Fisher's fund discloses a new CRSP stake Billionaire Ken Fisher's Fisher Asset Management opened a new position of 77,960 CRISPR Therapeutics shares worth about $4.25 million as of June 30, per 13F filings. A well-known investor buying in can draw attention and fresh demand to a beaten-down stock, though the position is small relative to CRSP's size.
A new institutional buyer is a fresh, concrete signal of outside money coming into the stock.
Valuation debate: cheap on cash-flow models, fair on book value One model pegs fair value at $221.98, implying the stock is deeply undervalued, while analyst targets average $86.21 and price-to-book sits near the industry average. CRSP still loses money on tiny revenue, so whether it is cheap depends entirely on assumptions about future Casgevy and pipeline sales. That uncertainty cuts both ways.
It frames the central bull-bear tension behind the stock's price without repeating any single event.

July 202618 Jun – 22 Jul 2026

▲3

Casgevy label expansion and pipeline catalysts drive CRISPR's long-term story

Casgevy approved for toddlers, adding billions in market The FDA expanded Casgevy's approval to children as young as two, adding about 5,500 U.S. patients and a potential $12.1 billion opportunity at $2.2 million per treatment. CRISPR shares 60:40 profits with Vertex, so this directly grows future revenue.
This is the biggest concrete new event that expands the commercial market for CRISPR's only approved drug.
New DNA-shredding CRISPR tool could widen the field Scientists unveiled a CRISPR-based tool that kills diseased cells by shredding their DNA, potentially treating cancers that affect 40-50% of patients. CRISPR Therapeutics doesn't own it, but its existing delivery infrastructure could give it an edge if the field grows.
It shows the gene-editing market expanding, which supports the long-term investment case for CRISPR.
Pipeline catalysts: cholesterol drug, clot therapy, CAR-T Analysts point to upcoming CTX310 cholesterol trial results, a new partnership for clot-prevention therapy CTX611, and an off-the-shelf CAR-T cancer program as future growth drivers. Cathie Wood's Ark holds $362 million in CRSP, betting on these catalysts.
These pipeline programs are the main reasons investors expect CRISPR to grow beyond Casgevy.
Slow Casgevy sales and losses offset by $2.4B cash CRISPR reported only $1.46 million in quarterly revenue and a $122.9 million net loss, as Casgevy adoption stays slow due to complex treatment procedures. Still, $2.4 billion in cash gives it years of funding, and treatment centers are increasing.
This is the main counterweight: the company is still far from profitable, which limits near-term upside.

18 Jun – 22 Jul 2026

▲3

Casgevy label expansion and pipeline catalysts drive CRISPR's long-term story

Casgevy approved for toddlers, adding billions in market The FDA expanded Casgevy's approval to children as young as two, adding about 5,500 U.S. patients and a potential $12.1 billion opportunity at $2.2 million per treatment. CRISPR shares 60:40 profits with Vertex, so this directly grows future revenue.
This is the biggest concrete new event that expands the commercial market for CRISPR's only approved drug.
New DNA-shredding CRISPR tool could widen the field Scientists unveiled a CRISPR-based tool that kills diseased cells by shredding their DNA, potentially treating cancers that affect 40-50% of patients. CRISPR Therapeutics doesn't own it, but its existing delivery infrastructure could give it an edge if the field grows.
It shows the gene-editing market expanding, which supports the long-term investment case for CRISPR.
Pipeline catalysts: cholesterol drug, clot therapy, CAR-T Analysts point to upcoming CTX310 cholesterol trial results, a new partnership for clot-prevention therapy CTX611, and an off-the-shelf CAR-T cancer program as future growth drivers. Cathie Wood's Ark holds $362 million in CRSP, betting on these catalysts.
These pipeline programs are the main reasons investors expect CRISPR to grow beyond Casgevy.
Slow Casgevy sales and losses offset by $2.4B cash CRISPR reported only $1.46 million in quarterly revenue and a $122.9 million net loss, as Casgevy adoption stays slow due to complex treatment procedures. Still, $2.4 billion in cash gives it years of funding, and treatment centers are increasing.
This is the main counterweight: the company is still far from profitable, which limits near-term upside.

Precigen Inc (PGEN)

Q3 202615 Jul – 5 Oct 2026

▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.
The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.
Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.
This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.
FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.
The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.
Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.
This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.

August 202615 Jul – 5 Oct 2026

▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.
The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.
Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.
This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.
FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.
The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.
Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.
This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.

Latest15 Jul – 5 Oct 2026

▲3▼1

Papzimeos Sales Boom and FDA Platform Win Drive PGEN Higher

Q2 earnings blow past estimates Precigen reported Q2 2026 GAAP EPS of $0.05, beating estimates by $0.06, and revenue of $54.98 million, beating forecasts by $27.15 million. This is the first clear proof the company can sell its drug at scale, which supports a higher stock price.
The earnings beat is the fundamental catalyst that validates the commercial launch and re-rates the stock.
Papzimeos sales more than double sequentially Papzimeos, the only approved therapy for recurrent respiratory papillomatosis, brought in $74.6 million in the first half of 2026, with Q2 sales more than doubling from Q1. Management says demand kept growing into Q3, showing the launch is still accelerating.
This is the core revenue driver behind the stock's 52.5% three-month gain and the main reason investors are bullish.
FDA platform designation opens pipeline upside The FDA granted platform technology designation to Precigen's AdenoVerse platform, which underpins Papzimeos and the experimental PRGN-2009 for HPV-related cancers. This could speed up and de-risk future drug approvals, adding value beyond the current one marketed product.
The designation expands the long-term opportunity and is a fresh regulatory win that supports the bull case.
Valuation and competition are real risks PGEN trades at 32.4 times sales, far above the biotech group average of 12.1 times, so any disappointment could hit hard. Rival Inovio's competing RRP therapy faces an FDA decision on Oct. 30, 2026, which could challenge Papzimeos's market lead.
This is the main counterweight: a stretched valuation and a near-term competitive threat that could reverse gains.